No­var­tis’ $9.7B PC­SK9 drug nabs first OK — now comes the chal­lenge of find­ing a mar­ket

A year af­ter No­var­tis wa­gered $9.7 bil­lion on The Med­i­cines Com­pa­ny and its PC­SK9 drug, in­clisir­an is set for its first launch.

The EU has ap­proved the RNAi ther­a­py, chris­tened Leqvio, for adults with hy­per­c­ho­les­terolemia or mixed dys­lipi­demia. Orig­i­nal­ly de­vel­oped on Al­ny­lam’s plat­form, it low­ers low-den­si­ty lipopro­tein cho­les­terol — the bad kind — by turn­ing off the pro­duc­tion of PC­SK9 at its source.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER